Calcein assay: A high-throughput method to assess P-gp inhibition

Xenobiotica

Volumn 41, Issue 8, 2011, Pages 712-719

  Glavinas, H ^a   Von Richter, O ^b   Vojnits, K ^a   Mehn, D ^a   Wilhelm, I ^c   Nagy, T ^a   Janossy, J ^a   Krizbai, I ^c   Couraud, P ^d,e,f   Krajcsi, P ^a  

^a SOLVO BIOTECHNOLOGY   (Hungary)

^b AiCuris GmbH   (Germany)

^c INSTITUTE OF BIOCHEMISTRY   (Hungary)

^d INSTITUT COCHIN   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

ABCB1; DDI; hCMEC D3; high throughput; K562MDR; MDCKII MDR1; Transporter

Indexed keywords

AMPRENAVIR; CALCEIN; COLCHICINE; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; DIPHENHYDRAMINE; ELACRIDAR; ERYTHROMYCIN; FEXOFENADINE; GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PRAZOSIN; PROPRANOLOL; QUINIDINE; RANITIDINE; TRIAMTERENE; TRIMETHOPRIM; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR;

ARTICLE; DRUG ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; PROTEIN EXPRESSION;

CELL LINE; DRUG INTERACTIONS; FLUORESCEINS; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; P-GLYCOPROTEIN; SENSITIVITY AND SPECIFICITY;

EID: 79960168196     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.587033     Document Type: Article

References (59)

1. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. (2006). Characterization of α-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 20:273-282.
2. Belli S, Elsener PM, Wunderli-Allenspach H, Krämer SD. (2009). Cholesterol-mediated activation of P-glycoprotein: Distinct effects on basal and drug-induced ATPase activities. J Pharm Sci 98:1905-1918.
3. Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, Drewe J. (2005).P-glycoprotein and surfactants: Effect on intestinal talinolol absorption. Clin Pharmacol Ther 77:24-32. (Pubitemid 40075386)
4. Brown CD, Sayer R, Windass AS, Haslam IS, De Broe ME, D'Haese PC, Verhulst A. (2008).Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 233:428-438.
5. Bubik M, Ott M, Mahringer A, Fricker G. (2006).Rapid assessment of p-glycoprotein-drug interactions at the blood-brain barrier. Anal Biochem 358:51-58. (Pubitemid 44511896)
6. Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, Lee CA. (2010).Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 7:398-411.
7. Dantzig AH, de Alwis DP, Burgess M. (2003).Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55:133-150. (Pubitemid 36078455)
8. Draheim V, Reichel A, Weitschies W, Moenning U. (2010). N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur J Pharm Sci 41:201-209.
9. de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. (2007). Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 96:2808-2817. (Pubitemid 47597829)
10. Eagling VA, Profit L, Back DJ. (1999).Inhibition of the CYP3A4- mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543-552. (Pubitemid 29454235)
11. EMA Guideline on the Investigation of Drug Interactions, 2010: EUROPEAN MEDICINES AGENCY (22 April 2010) Guideline on the Investigation of Drug Interactions (Online) Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2010/05/WC500090112.pdf. Accessed on 10 Jan 2011.
12. Englund G, Rorsman F, RÖnblom A, Karlbom U, Lazorova L, Gråjö J, Kindmark A, Artursson P. (2006).Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269-277. (Pubitemid 44602404)
13. Elsby R, Surry DD, Smith VN, Gray AJ. (2008).Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140-1164.
14. FDA concept paper. (2004).Drug Interaction Studies-Study design, data analysis, and implications for dosing and labeling Preliminary Concept Paper presented at the Food and Drug Administration Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology Subcommittee meeting, November 3, 2004. Available online at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/ 2004-4079B1-04-Topic2-TabA.pdf Accessed on 10 Jan 2011.
15. FDA Guidance for Industry. (2006).Guidance for industry, drug interaction studies-Study design, data analysis, and implications for dosing and labeling draft guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (September 2006) Clinical Pharmacology. Available online at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf Accessed on 10 Jan 2011.
16. Gatlik-Landwojtowicz E, A äismaa P, Seelig A. (2006).Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45:3020-3032. (Pubitemid 43334550)
17. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek- Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010).Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
18. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV. (2000). Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol 173:203-214. (Pubitemid 30100212)
19. Guo A, Marinaro W, Hu P, Sinko PJ. (2002).Delineating the contribution of secretory transporters in the efflux of etoposide using Madin- Darby Canine Kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 30:457-463. (Pubitemid 34263832)
20. Hamada A, Miyano H, Watanabe H, Saito H. (2003).Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307:824-828. (Pubitemid 37310701)
21. HollZ, Homolya L, Davis CW, Sarkadi B. (1994).Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191:384-388. (Pubitemid 24183562)
22. Hsing S, Gatmaitan Z, Arias IM. (1992).The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 102:879-885.
23. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008).New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670. (Pubitemid 351713150)
24. Hunter J, Hirst BH, Simmons NL. (1993).Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10:743-749. (Pubitemid 23152323)
25. Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgr é JJ, MÖkkÖen J. (2005).Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci 26:266-279. (Pubitemid 41278633)
26. Korjamo T, Kemil änen H, Heikkinen AT, MÖkkÖen J. (2007). Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab Dispos 35:1574-1579. (Pubitemid 47296050)
27. Lee CA, Cook JA, Reyner EL, Smith DA. (2010).P-glycoprotein related drug interactions: Clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 6:603-619.
28. Lee CA, Hillgren KM, Zhang L, Polli JW. (2011).Response from the International Transporter Consortium. Nat Rev Drug Discov 10:75.
29. Litman T, Skovsgaard T, Stein WD. (2003).Pumping of drugs by P-glycoprotein: A two-step process? J Pharmacol Exp Ther 307:846-853. (Pubitemid 37494200)
30. Lowes S, Cavet ME, Simmons NL. (2003).Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 458:49-56. (Pubitemid 36050700)
31. Ma JD, Tsunoda SM, Bertino JS Jr, Trivedi M, Beale KK, Nafziger AN. (2010).Evaluation of in vivo P-glycoprotein phenotyping probes: A need for validation. Clin Pharmacokinet 49:223-237.
32. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. (2000).Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
33. Markoutsa E, Pampalakis G, Niarakis A, Romero IA, Weksler B, Couraud PO, Antimisiaris SG. (2011).Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur J Pharm Biopharm 77:265-274.
34. Maubon N, Le Vee M, Fossati L, Audry M, Le Ferrec E, Bolze S, Fardel O. (2007).Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 21:659-663. (Pubitemid 350151254)
35. Meyers MB, Scotto KW, Sirotnak FM. (1991).P-glycoprotein content and mediation of vincristine efflux: Correlation with the level of differentiation in luminal epithelium of mouse small intestine. Cancer Commun 3:159-165.
36. Molná J, Kars MD, Güdü U., Engi H, Schumacher U, Van Damme EJ, Peumans WJ, Makovitzky J, Gyáét N, Molná P. (2009). Interaction of tomato lectin with ABC transporter in cancer cells: Glycosylation confers functional conformation of P-gp. Acta Histochem 111:329-333.
37. Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, Chieli E. (2006). Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br J Pharmacol 148:682-687. (Pubitemid 43993058)
38. Pá A, Mén D, Molná E, Gedey S, Mzáos P, Nagy T, Glavinas H, Jany T, von Richter O, Bhori G, Szente L, Krajcsi P. (2007). Cholesterol potentiates ABCG2 activity in a heterologous expression system: Improved in vitro model to study function of human ABCG2. J Pharmacol Exp Ther 321:1085-1094. (Pubitemid 46762703)
39. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. (1999).Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206-1212. (Pubitemid 29393608)
40. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. (2001).Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
41. Pradaxa (dabigatran etexilate).Summary of product characteristics. Available online at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000829/WC500041059.pdf last updated 03/2009. Accessed on 10 Jan 2011.
42. PubChem database. (2006).ATP-binding cassette sub-family B member 1 (Homo sapiens), calcein AM assay. Natl Center Biotechnol Inf., Bethesda, MD, USA, PubChem: 2006. (Online) Available at: http://pubchem.ncbi.nlm.nih.gov/summary/ summary.cgi?cid = 2521Accessed on 10 Jan 2011.
43. Rajnai Z, Mén D, Bey E, Okyar A, Jani M, Th GK, F F, LI F, Krajcsi P. (2010).ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos 38:2000-2006.
44. Rasilez (aliskiren hemifumarate).Summary of product characteristics. (Online) Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000964/WC500047220.pdf last updated 03 /2009. Accessed on 10 Jan 2011.
45. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. (2006).In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab Dispos 34:786-792.
46. Rebello S, Leon S, Hariry S, Dahlke M, Jarugula V. (2011).Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. J Clin Pharmacol 51:218-228.
47. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. (1992).Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267:4854-4858.
48. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. (2003). Comparison of in vitro P-glycoprotein screening assays: Recommendations for their use in drug discovery. J Med Chem 46:1716-1725. (Pubitemid 36444224)
49. Seelig A. (2007).The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J Mol Neurosci 33:32-41. (Pubitemid 47574956)
50. Shapiro AB, Ling V. (1997).Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137. (Pubitemid 27504592)
51. Shi JG, Zhang Y, Yeleswaram S. (2011).The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nat Rev Drug Discov 10:75; author reply 75.
52. Smalley J, Marino AM, Xin B, Olah T, Balimane PV. (2007).Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay. J Chromatogr B Analyt Technol Biomed Life Sci 854:260-267. (Pubitemid 46962390)
53. Szeréy P, Pá A, Mén D, Th B, F F, Krajcsi P, Heri-Szabö K. (2011).Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds. J Biomol Screen 16:112-119.
54. Taipalensuu J, Tönblom H, Lindberg G, Einarsson C, Sjövist F, Melhus H, Garberg P, Sjötrö B, Lundgren B, Artursson P. (2001). Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170. (Pubitemid 32905131)
55. Tang F, Horie K, Borchardt RT. (2002).Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:765-772. (Pubitemid 34686734)
56. Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J. (2005).The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys J 88:715-738. (Pubitemid 40070714)
57. von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K. (2009).A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol 379:11-26.
58. Weksler BB, Subileau EA, Perrie N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. (2005). Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872-1874. (Pubitemid 41598779)
59. Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. (2008).A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.